Nasdaq
$1.84▲ 2.22%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.1MShares out 2.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 2d agoAfter-hours26.10.23 05:37DEF 14AOther#●●●#●●●#●●●
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals completed its merger with Vidya Therapeutics on July 28, 2026, alongside a $200 million private placement. The company has scheduled a special meeting of stockholders for November 30, 2026, to vote on a reverse stock split proposal at a ratio between 1-for-3 and 1-for-9 to meet Nasdaq listing requirements.…more
$1.84+2.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.9After-hours26.10.10 05:55PRE 14AOther
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals completed its merger with Vidya Therapeutics on July 28, 2026, and issued Series A Preferred Stock through a $200 million private placement. The upcoming special meeting seeks stockholder approval for the conversion of these shares into common stock, the 2027 equity incentive plan, and the 2027 ESPP. Upon approval and Nasdaq listing compliance, the company plans to rename itself to Vidya Therapeutics, Inc. and trade under the ticker symbol VDYA.…more
$1.84+2.22%vs prev closeView filingShare - 10.9After-hours26.10.10 05:03PRE 14AOther
Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals has completed its merger with Vidya Therapeutics and a $200 million private placement. The company is convening a special meeting of stockholders to approve a reverse stock split at a ratio between 1-for-3 and 1-for-9 to meet Nasdaq listing requirements and facilitate a name change.…more
$1.84+2.22%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.9After-hours26.10.10 05:05Bullish#●●●#●●●
Processa Pharmaceuticals Files Prospectus For 306.57M Share Offering
Processa Pharmaceuticals has filed a prospectus for the offering of 306.57 million common shares on behalf of selling shareholders. This large-scale issuance may lead to shareholder dilution, negatively impacting the stock price.…more
$1.84+2.22%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 7.29Pre-market26.07.29 20:30
●●●●●●●● ●●●●● ●●●●●●
프로세사 파마슈티컬스가 비디아 테라퓨틱스를 인수하고 2억 달러 규모의 사모펀드 조달을 통해 차세대 BTK 억제제 개발에 나섭니다. 이번 대규모 자금 확보로 임상 파이프라인 가속화가 기대되나, 대규모 신주 발행에 따른 기존 주주 가치 희석 가능성도 존재합니다.…more
$1.84+2.22%vs prev close
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report